Hemispherx Biopharma Inc (HEB)

0.13
0.00 2.37
AMEX : Health Care
Prev Close 0.12
Open 0.12
Day Low/High 0.11 / 0.13
52 Wk Low/High 0.06 / 0.21
Volume 873.91K
Avg Volume 591.20K
Exchange AMEX
Shares Outstanding 247.92M
Market Cap 32.23M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Hemispherx Biopharma Enters Into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes With Insurance Carriers, And Obtaining Commitments Of $3.5 Million In Payments To Company

Hemispherx Biopharma Enters Into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes With Insurance Carriers, And Obtaining Commitments Of $3.5 Million In Payments To Company

CEO Says Series of Coordinated Settlements Should Allow the New Management Team to Focus Exclusively on the Company's Long-Term Commercial, Research and Financial Objectives

Hemispherx Biopharma Renews Sales, Marketing, Distribution And Supply Agreement With GP Pharm

Hemispherx Biopharma Renews Sales, Marketing, Distribution And Supply Agreement With GP Pharm

Initial Target is ANMAT Approval to Treat Chronic Fatigue Syndrome Patients in Argentina

Insider Trading Alert - HEB, EPAY And STOR Traded By Insiders

Insider Trading Alert - HEB, EPAY And STOR Traded By Insiders

Stocks with insider trader activity include HEB, EPAY and STOR

Hemispherx Biopharma Reviews Ampligen® Data With National Institute Of Neurological Disorders And Stroke (NINDS)

Hemispherx Biopharma Reviews Ampligen® Data With National Institute Of Neurological Disorders And Stroke (NINDS)

National Institutes of Health Research Focus on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is Set to be a Game Changer for Patients

Hemispherx Biopharma Introduces A Voluntary Stock Purchase Plan To Create Shareholder Value

Hemispherx Biopharma Introduces A Voluntary Stock Purchase Plan To Create Shareholder Value

Senior Management, Entire Board of Directors, and 100% of All Employees Participate

Hemispherx Biopharma Announces Financial Results For The Nine Months Ended September 30, 2015

Hemispherx Biopharma Announces Financial Results For The Nine Months Ended September 30, 2015

Long Term Exclusivity in Promising Novel Nucleic Acid Treatments Supported by Recent Issuance of a Broad Patent in European Union

Hemispherx Biopharma Reports Low NK Cell Activity In Chronic Fatigue Syndrome (CFS) And Relationship To Disease Symptoms

Hemispherx Biopharma Reports Low NK Cell Activity In Chronic Fatigue Syndrome (CFS) And Relationship To Disease Symptoms

Ampligen(R) Increases NK Activity More Than 100% in Vitro in a CFS Patient Population